ArticleHealthcare (Basel, Switzerland)2023
Triple Primary Malignancies: Tumor Associations, Survival, and Clinicopathological Analysis: A 25-Year Single-Institution Experience.
Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Higher-order multiple primary cancers and persistent cross-site risk across human papillomavirus-related anatomical sites in the United States: a population-based Surveillance, Epidemiology, and End Results study.Preventive medicine reports · 2026Article
- Article
- Long-term survival in a case report with metachronous quadruple primary malignancies involving multiple organ systems.Discover oncology · 2026Article
- Rare occurrence of triple primary malignant tumors: Dermatofibrosarcoma protuberans, lung adenocarcinoma and papillary thyroid carcinoma in a patient with genetic evaluation.Radiology case reports · 2025Article
- Trifecta of Tumors: Simultaneous Detection of Three Primary Malignancies by Different Radiotracers of Nuclear Medicine.World journal of nuclear medicine · 2024Article
- Multiple primary malignancies: sequential development of Ewing sarcoma and carcinoid tumor in a single patient.Annals of medicine and surgery (2012) · 2024Article
- Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.World journal of methodology · 2024Review
- Pembrolizumab plus Lenvatinib for Synchronous Triple Primary Malignancies of the Kidney, Bladder, and Liver: Clinical Implications of Conflict of Drug Doses and Dominant Tumor Biology.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of multiple primary malignancies is on the rise despite their rare occurrence rate. This research aims to determine the prevalence, tumor association patterns, overall survival, and the correlation between survival time and independent factors in patients with triple primary malignancies. This single-center retrospective study included 117 patients with triple primary malignancies admitted to a tertiary cancer center between 1996 and 2021. The observed prevalence was 0.082%. The majority of patients (73%) were over the age of fifty at the first tumor diagnosis, and regardless of gender, the lowest median age occurred in the metachronous group. The most common tumor associations were found between genital-skin-breast, skin-skin-skin, digestive-genital-breast, and genital-breast-lung cancer. The male gender and being over the age of fifty at the first tumor diagnosis are associated with a higher risk of mortality. Compared with the metachronous group, patients with three synchronous tumors demonstrate a risk of mortality 6.5 times higher, whereas patients with one metachronous and two synchronous tumors demonstrate a risk of mortality three times higher. The likelihood of subsequent malignancies should always be considered throughout cancer patients' short- and long-term surveillance to ensure prompt tumor diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.